‘Unimaginable': Heartbreak as Melbourne dad, 36, dies suddenly
Ashlee Tyrrell, 32, had recently returned to work after spending almost a decade at home while welcoming three kids with her fiance of 13-years, Shaun Skinner, 36.
But just days into her new job at Baby Bunting, Ashlee received a call that turned her life upside down: It was Shaun, telling her his pacemaker had 'gone off'.
The 36-year-old had been diagnosed with cardiomyopathy (HCM), a disease of the heart muscle that makes it harder for the vital organ to pump blood effectively, at age 17 after collapsing while playing basketball.
But after having a pacemaker fitted, and following a 'heart smart' lifestyle that included avoiding alcohol and strenuous exercise, Ashlee said he'd 'never had any issues'.
'We just thought, maybe he'd overdone it, it wasn't something that made us go, 'oh, this is bad,' Ashlee told news.com.au.
'The medical device, which helps regulate the heart's rhythm by sending electrical impulses to the heart muscle, had only ever gone off once since Shaun had it fitted as a teenager and that was because he had over exerted himself.
'So we didn't panic, but I told him to sit tight, and that I would come straight home.'
But just 10 minutes into the half-hour drive home, Ashlee got another call, this time from ambos en-route to the couple's home.
'That morning, our youngest two were sick, and because I had a new job, it was still quite fresh, Shaun offered to stay home and look after them so I could go in,' she explained.
'Ambulance Victoria called and said Shaun had phoned them. They said he was 'terrified' because he was home alone with our 3-year-old, Everly, and our 7-year-old, Violet, and he knew he needed someone with the kids.'
Tragically, by the time Ashlee made it home, Shaun's condition had only worsened.
'When I got to the house, there was a fire engine, more than one ambulance and a police car, I knew,' she said.
'I got out of the car and saw a paramedic, and I asked, 'Is he OK?'
'She told me he was very sick and it was not what I expected. I thought I would get to see him, I though I'd get there, and he would be sitting on the couch, like, 'I'm alright'.'
Paramedics worked tirelessly to revive Shaun, but after 45-minutes, he was pronounced dead after suffering an unexpected heart attack, something Ashlee said 'still doesn't feel real'.
'We were getting married next year,' she explained through tears. 'It was something we kept putting off because of the kids, but it was finally happening.
'But after they said, 'I'm sorry, there's nothing more we can do', my whole life crashed in a matter of seconds.'
In Australia, a person with HCM will generally have a typical life expectancy, especially if they follow a heart-healthy lifestyle. However, a small number of people are at risk for major complications, including sudden death and heart failure.
Ashlee and their three daughters – including 9-year-old Sophie who was brought home from school early – all said goodbye to Shaun at home before his body was taken by the coroner. The results of an autopsy will be released in 16 weeks.
One of the most heartbreaking details from the ordeal, which occurred on August 4, was learning that when paramedics arrived on the scene, little Everly was lying on top of her daddy, giving him cuddles.
'I love him so much, I know he was holding on for the paramedics to arrive, just to make sure our girls were being looked after,' Ashlee said.
'He didn't pass out until someone was there for them. The last thing he said to Violet was, 'it's OK, Daddy loves you'. Those were his last words.'
Ashlee's best friend Jasmine Marshall has since launched a GoFundMe page to help the grief-stricken family as they face the 'unimaginable tragic loss' of life without Shaun.
'Until a couple of weeks before his death, Shaun was the main provider for our family,' Ashlee said.
The pair met when she was just 18, when Ashlee got a job on the reception desk at the office where for a door, wardrobe and splashback manufacturer where Shaun worked. They got engaged a year later
'He had been in his job for 15 years. He loved it. He was such a great dad and partner.'
The heartbroken mum is now focusing on helping their daughters navigate this difficult time, but said she can't help but question whether there was more they could have done.
'It was out of nowhere, you can't help but think 'maybe I should have known it was coming', but there was no way to know,' she said.
'But he'd never had any problems, his heart condition was almost mundane, we didn't even think about it because there was never any issues.
'I'm not silly, I knew he wasn't going to live to be 100, but I didn't think I would lose him young. He took his medication every day, we had no inkling, lots of people have this condition and live long, healthy lives, his grandfather had it and lived to be an old man.
'We had no idea it would be something that would take him away from us.'
Despite losing Shaun so suddenly, Ashlee wanted to thank the emergency services who were here for her during the 'worst moment of my life'.
'Everyone that was there that day, the paramedics, the police, were the most gentle, kindest people. They tried so hard to save him. They made sure we were protected from that things we weren't supposed to see and I am so grateful they saved my little girls from that.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 minutes ago
- ABC News
How does our environment impact our health? Unravelling the exposome
With around 125,000 children and parents enrolled, Generation Victoria — or GenV — is set to become one of the largest health studies of its kind in the world. But its scientific director, Melbourne paediatrician Melissa Wake, says at its heart is a "simple idea". "At a population level, more people are dying from diseases that we ought to be able to prevent … and it's now become clear that children are likely to face shorter life spans than their parents," Professor Wake says. "We asked ourselves: How can we change the life trajectories of our population through research? How can we help people to live their longest and healthiest lives?" In 2021, Professor Wake and her colleagues at the Murdoch Children's Research Institute began recruiting for Generation Victoria or GenV, a major long-term study that will track the health of more than 50,000 babies born in Victoria between 2021 and 2023 — and their parents — over their lifetime. The aim of the research is to understand what shapes health and wellbeing across our early years and mid-life, and to identify factors that contribute to the development of disease. "We're interested in long-term [health] outcomes … things like cancer, heart disease, stroke, osteoporosis and Alzheimer's," Professor Wake says. "But also things that children experience now — like poor mental health, asthma, ADHD, autism and obesity." While other large studies have set out to answer similar questions, Professor Wake says technological advances mean researchers are now able to capture health data in more detail at vastly bigger scales. "The idea is to work with people across an entire population, try and measure all of the layers that we know are important to health, and then learn how we can actually improve [disease] prevention pathways." To do this, researchers will capture information about participants' DNA, as well as the physical, chemical, psychological and social conditions they're exposed to — known collectively as the human "exposome". The exposome is a measure of all the environmental or external exposures we face over our lifetime and the ways in which these impact our health. It includes everything from diet, lifestyle, education and income to air pollution, chemical exposures, and climate conditions. "Many of [these factors] overlap and happen in unequal ways, so if you're born and grow up in a poor area, your exposome is likely to be shaped by external stressors, air pollution, fewer opportunities and less income," Professor Wake says. It also encompasses internal processes, such as as your microbiome (or gut bacteria), inflammatory processes and metabolic factors, that are that are shaped, at least in part, by external exposures. Johns Hopkins University researcher Fenna Sillé says while almost all diseases have a genetic component, the exposome often plays a critical role, particularly in the development of chronic diseases. "It's estimated that up to 70 per cent — and for some [chronic] diseases even 90 per cent — of the risk is due to environmental exposures," Dr Sillé told the Health Report. In May, a group of international researchers, including Dr Sillé, convened in the US to establish the Human Exposome Project — a global effort to "systematically map the totality of environmental exposures and their effects on human biology". "The idea has lived for a while now of starting something that complements the Human Genome Project, but it's obviously not a small feat," she says. The field of exposomics research has grown in recent years, particularly in Europe, where researchers have been investigating the relationship between environmental exposures and conditions such as chronic obstructive pulmonary disease, type 1 diabetes, coeliac disease, allergies and asthma. While studying how environmental factors influence human health is not a novel idea, advancements in AI and computational models mean scientists can "really start to deal with" the complexity of overlapping and interacting exposures, University of Queensland epidemiologist and toxicologist Nick Osborne says. "In the past, we'd look at one toxin … and we'd see what the effect was. But, of course, that's not the real world," says Dr Osborne. "In the real world … there are a lot of [exposures] happening at once. "[The exposome] is about having an understanding that the body is a very complex system but it's also interfacing with a very complex environment." In Australia and other high-income countries, dramatic increases in cancer rates among young people in recent years has prompted concern that widespread environmental changes are contributing to earlier diagnoses. Research suggests a surge in obesity, sedentary lifestyles, and increased exposure to plastics may all be playing a role, as well as changes to young people's gut bacteria from eating ultra-processed food and using more antibiotics. "There's a very strong relationship between our gut bacteria and our immune system and brain and many of the functions in the body," Dr Osborne says. "We're finding more and more that chronic inflammation seems to drive many of the 'big five' diseases we're confronted with — mental health, diabetes, cancer, heart disease and asthma." But untangling the effects of different exposures is challenging, Dr Osborne says, in part because many diseases appear to be the result of a complex interaction between our environment and our genes. "Quite often you might have the 'bad' genes, but if you're not exposed to the 'bad' environment, you don't get the disease," he says. While it's impossible to document and study everything humans are exposed to, Professor Wake says the goal of GenV was to understand and act on the most important disease pathways and exposures. "It would be nice to know everything, but what we really need to know are the most important things, and we need to act on the most important things." The ways in which researchers measure the health impacts of different exposures varies, and in some cases, involves looking at an individuals' physiological processes, Dr Sillé says. "Even though you can't measure everything every day … there are the exposures, both internal and external, that leave some sort of imprint." Epigenetic effects, which include changes to the way your genes work as a result of your behaviours and environment, are one example. "But also your metabolism, for example … is affected by things that happened in your past." Initially, GenV researchers will mostly rely on existing clinical records and biological samples that are routinely collected during pregnancy and early childhood, such as blood samples. Parents will also be invited to provide saliva and breastmilk samples, as well as information (through an app) about their children's physical and mental health during their early years. "Our ethos has been that if you have 125,000 [participants] … it has to be very easy for them to take part," Professor Wake says. As the children in the study grow up, more detailed health data will be collected from them at ages 6, 11 and 16, as well as from their parents. "We'll be trying to measure those important [disease] development pathways for children and parents," Professor Wake says. "Things like: what's happening to their blood pressure? What's happening with their growth, their body composition? What's actually happening in their brains? "What we are wanting to do is actually measure the health signals that lie between risk factors and the long-term outcomes we care about." Alongside measuring health markers, Professor Wake says researchers will collect family- and community-level data, as well as information about "air quality, climate, built environments, shopping opportunities, food supply" and other layers of the exposome. To do this, they will rely on things like satellite maps, ambient monitors in classrooms and homes, environmental datasets and "social and policy mapping" tools. A key advantage of the study, Professor Wake says, is the ability for researchers to not only observe changes over time, but also test the effectiveness of different health interventions. "One of the ways to make discoveries is to undertake interventions," she says. "We are particularly interested in … actually testing: can we change [disease] risk? How much can we change risk? Does it make a difference to the outcomes that matter? Who for? And is it fair? "And because we've got that long-term horizon, we should be able to look 20, 30, 40 years down the track."
News.com.au
2 minutes ago
- News.com.au
Morgans spotlights nine healthcare stocks with upcoming catalysts after 'upbeat' Bioshares Biotech Summit
Morgans' Scott Power describes mood at Bioshares Biotech Summit as "markedly more upbeat than prior years" with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-term catalysts over next three to six months Results from Argenica's phase II trial of lead product ARG-007 in acute ischaemic stroke patients expected in early September In a further positive sign the ASX healthcare sector may be recovering, Morgans' senior healthcare analyst Scott Power has returned from the 19th annual Bioshares Biotech Summit, describing the mood of presenting companies as "markedly more upbeat than prior years". The summit, which featured presentations from more than 30 biotech companies, followed a strong July for the healthcare sector, which rose 9.05% to be best performer of the 11 ASX sectors. While healthcare remains the worst-performing sector YTD, up just 1.81%, the solid July results and positive momentum at this year's Bioshares conference signals a positive turnaround. Attended by analysts along with institutional and high net worth investors, Stockhead's Tim Boreham refers to the summit as the "Druggies & Dealers' conference – a playful nod to the well-known annual Diggers & Dealers mining forum, which this year fell in the same week. "The conference was centred on the evolution and strategic positioning of Australian biotech companies across the drug development lifecycle, with a strong emphasis on innovation and commercialisation," Power said. "We generally got the sense there is a lot more happening in the background for many of these companies than first glance." Power has highlighted nine ASX healthcare companies presenting at the summit with clear near-term catalysts over the next three to six months. Morgans nine ASX healthcare stocks with upcoming catalysts Neuren Pharmaceuticals (ASX:NEU) Market cap: $2.2 billion Neuren develops drugs for the treatment of neurological disorders and became the darling of the ASX biotech sector in 2023 when trofinetide, marketed as DAYBUE, received US Food and Drug Administration approval as the first and only approved treatment for Rett syndrome – a rare neurological disorder mostly affecting girls and emerging in infancy. Acadia Pharmaceuticals, Neuren's partner, markets DAYBUE in North America with the Aussie biotech eligible to receive double-digit royalties payments. Power said the key upcoming catalyst for Neuren would be an expectation of continued improvement in DAYBUE net sales in Q3 CY25. The company's latest quarterly sales were US$96.1 million, up 14% on pcp. CogState (ASX:CGS) Market cap: $295.9 million Cogstate is a neuroscience technology company focused on optimising neurological health assessments to advance the development of new medicines and deliver clinical insights into brain function. Its Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of neurological performance, including processing speed, attention, visual learning, working memory and executive function. CogState has provided FY25 guidance of revenue between US$52 to US$54 million, up 20% to 24% and profit before tax between US$12 to US$14 million. "CGS will report its FY25 result on August 22 with the existing share buyback expected to be extended," Power said. Market cap: $95m The key upcoming catalyst for Argenica is results forecast for early September of a phase II trial of its lead product ARG-007 in acute ischaemic stroke patients. ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours after acute neurological events such as stroke, traumatic brain injury (TBI) and hypoxic brain damage. In April, Argenica completed dosing of 92 patients in the double-blinded, randomised, placebo controlled phase II trial undertaken at eight emergency departments around Australia. Data-read out from the trial is due in September with safety the main endpoint, determining if the drug asset can advance further in clinical development. Blinklab (ASX:BB1) Market cap:$55m Blinklab is a company founded by neuroscientists at Princeton University and has developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia and other neurodevelopmental conditions. "The key short term catalyst is the release of results for BB1's pilot study for autism involving around 190 children," Power said, "The study undertaken at two sites is on track to finish recruitment in August with data locking and unblinding to follow and results expected to be released in September. "A main phase trial is expected to follow recruiting up to 900 children across eight additional sites." Clever Culture Systems (ASX:CC5) Market capitalisation $62.4 million Adelaide-based Clever Culture Systems has developed the only US FDA-cleared AI technology for automated culture plate reading. Its APAS (automated plate assessment system) Independence instruments automatically analyse culture plates to detect microbial contamination, classifying growth as significant or non-significant. In sterile drug manufacturing, culture plates are used inside cleanrooms to monitor for contamination, with results critical to releasing safe and effective drugs. Clever Culture's APAS Independence reduces the time consuming manual analysing of the culture plates by microbiologists. "CC5 has signed up three large pharmaceutical companies including AstraZeneca, Bristol Myers Squibb and Novo Nordisk plus two large lab companies and is in negotiations with other tier one groups," Power said. "Announcements around additional customers or expansion with existing customers is a key short-term catalyst." Tetratherix (ASX:TTX) Market cap: $215 million Wound management house Tetratherix made its ASX debut on June 30, breaking an IPO drought for the sector. Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO. Tetratherix has developed a proprietary polymer platform enabling the targeted delivery of cells, drugs and biologics, to treat a range of conditions across tissue spacing, bone regenerative and tissue healing. The company will post its maiden FY25 result in late August. "The near-term catalysts we expect to be called out include progress on the bone regeneration franchise which is targeting FDA clearance in H2 CY26 and an update on the recruitment in the trial for Cohort 2 using TetraDerm (tissue healing) involving surgical incisions in the face and neck," Power said. Micro-X (ASX:MX1) Market cap: $52 million Micro-X has proprietary cold cathode, carbon nanotube (CNT) emitter technology which is focused on medical imaging and security applications. The company recently announced a significant commercial milestone, a three-year supply agreement with a major US healthcare provider for its Rover Plus mobile radiology system. The deal followed a successful evaluation and competitive tender by the healthcare provider, which operates more than 700 facilities nationwide. It has added Rover Plus to its approved procurement list, allowing member hospitals to purchase the system without further evaluation or tendering. "We expect additional supply agreements will be executed over the near-term," Power said. Dimerix (ASX:DXB) Market cap: $300m Dimerix's lead drug candidate DMX-200 is in a phase III trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The ACTION3 phase III trial continues to recruit across clinical sites globally, with more than 190 sites activated. Full targeted recruitment of 286 patients for the ACTION3 trial is expected to be completed by the end of CY25. Dimerix is also developing DMX-700 for respiratory disease. "Following a positive interim analysis (Part 1) another interim analysis (Part 2) is expected to be released late CY25 or early CY26," Power said. Artrya (ASX:AYA) Market cap: $148m Artrya is developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software called Salix analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya has three key modules in its Salix platform. The FDA-cleared and launched Coronary Anatomy module is already in market. Power said upcoming catalysts for the company included FDA clearances of its Coronary Plaque module, expected in Q3 CY25, and its Coronary Flow module, anticipated in Q1 CY26. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
ABC News
32 minutes ago
- ABC News
Locust taskforce assembles in Longreach as plague threat grows
They resembled thick plumes of black smoke on the outback horizon, a concerning sight for grazier Geoff Seccombe. The reality was worse. It was a "massive swarm" of millions of locusts, 10 times bigger than those endured by his sheep, cattle and goats over the past five years. The locust outbreak could intensify to plague levels by spring, with experts warning only a small amount of rain is needed to supercharge the swarm. Federal and state agencies, along with local councils, will now meet weekly to respond to the swarms and prepare for a possible plague. Since April, graziers in central-west Queensland have been battling masses of migratory locusts that descend on pasture and strip it bare. The Remote Area Planning and Development Board (RAPAD) chairperson Tony Rayner said locusts could eat so much pasture it created a "mini drought". "A billion grasshoppers eat an enormous amount of pasture … 20 tonnes a day is a figure that's quoted and that equates to a triple road train of hay." A taskforce has now been set up as the regions grapple with the locusts and their path of destruction. Gregory MP Sean Dillon said the locusts posed a clear threat to grazing land, and to ongoing beef, sheep and cattle production. "That's why the department has stood up and is taking very seriously the oversight of these locusts," he said. The taskforce includes the Australian Plague Locust Commission (APLC), Department of Primary Industries, peak bodies and councils, and meets weekly in Longreach. It is the first time a locust taskforce has been assembled in western Queensland. Locusts usually pose more of a threat to areas reliant on crops. There are 19 "cropping councils" in Queensland that contribute to Biosecurity Queensland's Pest Plague Contingency Fund (PPCF) to help fund aerial spraying. It can be a costly control measure, especially for outback graziers who have so far not been able to access funding support. Mr Seccombe agreed it was "very expensive", and while his property still had plenty of feed, he would still stock up on hay. "It would cost around $60,000 [to spray]," he said. Queensland Locust Commissioner Michelle Smith said western Queensland councils, including Barcaldine and Longreach, had been invited to join the fund. For now, they are mostly outside the fund's spraying area. She said a deal had also been done with the federal government to use extra money set aside for flood disaster relief to help pay for "large-scale" aerial control. Spring and summer are the peak seasons for locusts. Australian Plague Locust Commissioner Bertie Hennecke said heavy rainfall in western Queensland created prime conditions for locust breeding, even through winter. Dr Hennecke said about 30 millilitres of rain a month over the coming months would be enough for the outbreak to become a plague. "If the rainfall is below that then we will see a similar situation to 2002 and 2015, that the locust populations are decreasing, eggs are not developing, and therefore the next generation won't develop into adults," he said.
